Emerging cytoprotective peptide therapies for stroke

References

• Schmidt-Pogoda A, Bonberg N, Koecke MHM, et al. Why most acute stroke studies are positive in animals but not in patients: a systematic comparison of preclinical, early phase, and phase 3 clinical trials of neuroprotective agents. Ann Neurol. 2020;87:40–51.
   PubMed Web of Science ®Google Scholar
• Rogalewski A, Schneider A, Ringelstein EB, et al. Toward a multimodal neuroprotective treatment of stroke. Stroke. 2006;37:1129–1136.
   PubMed Web of Science ®Google Scholar
• Meloni BP, Mastaglia FL, Knuckey NW. Cationic arginine-rich peptides (CARPs): a novel class of neuroprotective agents with a multimodal mechanism of action. Front Neurol. 2020;11:108.
   PubMed Web of Science ®Google Scholar
• Edwards AB, Mastaglia FL, Knuckey NW, et al. Neuroprotective cationic arginine-rich peptides (CARPs): a assessment of their clinical safety. Drug Saf. 2020. DOI:10.1007/s40264-020-00962-z
   PubMed Web of Science ®Google Scholar
• Meloni BP, Brookes LM, Clark VW, et al. Poly-arginine and arginine-rich peptides are neuroprotective in stroke models. J Cereb Blood Flow Metab. 2015;35:993–1004.
   PubMed Web of Science ®Google Scholar
• MacDougall G, Anderton RS, Ouliel E, et al. In vitro cellular uptake and neuroprotective efficacy of poly-arginine-18 (R18) and poly-ornithine-18 (O18) peptides: critical role of arginine guanidinium head groups for neuroprotection. Mol Cell Biochem. 2020;464:27–38.
   PubMed Web of Science ®Google Scholar
• Meloni BP, Milani D, Cross JL, et al. Assessment of the neuroprotective effects of arginine-rich protamine peptides, poly-arginine peptides (R12-cylic, R22) and arginine-tryptophan containing peptides following in vitro excitotoxicity and/or permanent middle cerebral artery occlusion in rats. Neuromolecular Med. 2017;19:271–285.
   PubMed Web of Science ®Google Scholar
• Hill MD, Goyal M, Menon BK, et al. Efficacy and safety of nerinetide for the treatment of acute ischaemic stroke (ESCAPE-NA1): a multicentre, double-blind, randomised controlled trial. Lancet. 2020;395:878–887.
   PubMed Web of Science ®Google Scholar
• Milani D, Clark VW, Cross JL, et al. Poly-arginine peptides reduce infarct volume in a permanent middle cerebral artery rat stroke model. BMC Neurosci. 2016;17:19.
   PubMed Web of Science ®Google Scholar
• Milani D, Knuckey NW, Cross JL, et al. The R18 polyarginine peptide is more effective than the TAT-NR2B9c (NA-1) peptide when administered 60 minutes after permanent middle cerebral artery occlusion in the rat. Stroke Res Treat. 2016;2016:1–9.
   Web of Science ®Google Scholar
• Milani D, Cross JL, Anderton RS, et al. Neuroprotective efficacy of R18 poly-arginine and NA-1 (TAT-NR2B9c) peptides following transient middle cerebral artery occlusion in the rat. Neurosci Res. 2017;114:9–15.
   PubMed Web of Science ®Google Scholar
• Milani D, Bakeberg MC, Cross JL, et al. Comparison of neuroprotective efficacy of poly-arginine R18 and R18D (D-enantiomer) peptides following permanent middle cerebral artery occlusion in the Wistar rat and in vitro toxicity studies. PLoS One. 2018;13:e0193884.
   PubMed Web of Science ®Google Scholar
• Meloni BP, South SM, Gill DA, et al. Poly-arginine peptides R18 and R18D improve functional outcomes after endothelin-1-induced stroke in the Sprague Dawley rat. J Neuropathol Exp Neurol. 2019;78:426–435.
   PubMed Web of Science ®Google Scholar
• Meloni BP, Chen Y, Harrison KA, et al. Poly-arginine peptide-18 (R18) reduces brain injury and improves functional outcomes in a nonhuman primate stroke model. Neurotherapeutics. 2020;17:627–634.
   PubMed Web of Science ®Google Scholar
• Lei B, James ML, Liu J, et al. Neuroprotective pentapeptide CN-105 improves functional and histological outcomes in a murine model of intracerebral haemorrhage. Sci Rep. 2016;6:34834.
   PubMed Web of Science ®Google Scholar
• A Proof of concept study to evaluate CN-105 in ICH patients (CATCH). 2020. Available from: https://clinicaltrials.gov/ct2/show/NCT03168581?term=NCT03168581&draw=2&rank=1
   Google Scholar
• Field randomization of NA-1 therapy in early responders (FRONTIER). 2019. Available from: https://clinicaltrials.gov/ct2/show/NCT02315443
   Google Scholar
• Aarts M, Liu Y, Liu L, et al. Treatment of ischaemic brain damage by perturbing NMDA receptor-PSD-95 protein interactions. Science. 2002;298:846–850.
   PubMed Web of Science ®Google Scholar
• Meloni BP, Milani D, Edwards AB, et al. Neuroprotective peptides fused to arginine-rich cell penetrating peptides: neuroprotective mechanism likely mediated by peptide endocytic properties. Pharmacol Ther. 2015;153:36–54.
   PubMed Web of Science ®Google Scholar
• Marshall J, Wong KY, Rupasinghe CN, et al. Inhibition of N-methyl-D-aspartate-induced retinal neuronal death by polyarginine peptides is linked to the attenuation of stress-induced hyperpolarization of the inner mitochondrial membrane potential. J Biol Chem. 2015;290:22030–22048.
   PubMed Web of Science ®Google Scholar
• Soriano FX, Martel MA, Papadia S, et al. Specific targeting of pro-death NMDA receptor signals with differing reliance on the NR2B PDZ ligand. J Neurosci. 2008;28:10696–10710.
   PubMed Web of Science ®Google Scholar
• Sun HS, Doucette TA, Liu Y, et al. Effectiveness of PSD95 inhibitors in permanent and transient focal ischaemia in the rat. Stroke. 2008;39:2544–2553.
   PubMed Web of Science ®Google Scholar
• Bratane BT, Cui H, Cook DJ, et al. Neuroprotection by freezing ischaemic penumbra evolution without cerebral blood flow augmentation with a postsynaptic density-95 protein inhibitor. Stroke. 2011;42:3265–3270.
   PubMed Web of Science ®Google Scholar
• Cook DJ, Teves L, Tymianski M. Treatment of stroke with a PSD-95 inhibitor in the gyrencephalic primate brain. Nature. 2012;483:213–217.
   PubMed Web of Science ®Google Scholar
• Hill MD, Martin RH, Mikulis D, et al. ENACT trial investigators. Safety and efficacy of NA-1 in patients with iatrogenic stroke after endovascular aneurysm repair (ENACT): a phase 2, randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2012;11:942–950.
   PubMed Web of Science ®Google Scholar
• Wang Z, Chen Z, Yang J, et al. Treatment of secondary brain injury by perturbing postsynaptic density protein-95-NMDA receptor interaction after intracerebral haemorrhage in rats. J Cereb Blood Flow Metab. 2019;39:1588–1601.
   PubMed Web of Science ®Google Scholar
• Edwards AB, Cross JL, Anderton RS, et al. Poly-arginine R18 and R18D (D-enantiomer) peptides reduce infarct volume and improves behavioural outcomes following perinatal hypoxic-ischaemic encephalopathy in the P7 rat. Mol Brain. 2018;11:8.
   PubMed Web of Science ®Google Scholar
• Liddle L, Reinders R, South S, et al. Poly-arginine-18 peptides do not exacerbate bleeding, or improve functional outcomes following collagenase-induced intracerebral haemorrhage in the rat. PLoS One. 2019;14:e0224870.
   PubMed Web of Science ®Google Scholar
• Elmquist A, Langel U. In vitro uptake and stability study of pVEC and its all-D analog. Biol Chem. 2003;384:387–393.
   PubMed Web of Science ®Google Scholar
• Najjar K, Erazo-Oliveras A, Brock DJ, et al. An L- to D-amino acid conversion in an endosomolytic analog of the cell-penetrating peptide TAT influences proteolytic stability, endocytic uptake, and endosomal escape. J Biol Chem. 2017;292:847–861.
   PubMed Web of Science ®Google Scholar
• James ML, Komisarow JM, Wang H, et al. Therapeutic development of apolipoprotein E mimetics for acute brain injury: augmenting endogenous responses to reduce secondary injury. Neurotherapeutics. 2020;17:475–483.
   PubMed Web of Science ®Google Scholar
• Laskowitz DT, Fillit H, Yeung N, et al. Apolipoprotein E-derived peptides reduce CNS inflammation: implications for therapy of neurological disease. Acta Neurol Scand Suppl. 2006;185:15–20.
   PubMedGoogle Scholar
• Tu TM, Kolls BJ, Soderblom EJ, et al. Apolipoprotein E mimetic peptide, CN-105, improves outcomes in ischaemic stroke. Ann Clin Transl Neurol. 2017;4:246–265.
   PubMed Web of Science ®Google Scholar
• Liu J, Zhou G, Kolls BJ, et al. Apolipoprotein E mimetic peptide CN-105 improves outcome in a murine model of SAH. Stroke Vasc Neurol. 2018;3:222–230.
   PubMedGoogle Scholar
• Laskowitz DT, Wang H, Chen T, et al. Neuroprotective pentapeptide CN-105 is associated with reduced sterile inflammation and improved functional outcomes in a traumatic brain injury murine model. Sci Rep. 2017;7:46461.
   PubMed Web of Science ®Google Scholar
• Guptill JT, Raja SM, Boakye-Agyeman F, et al. Phase 1 randomized, double-blind, placebo-controlled study to determine the safety, tolerability, and pharmacokinetics of a single escalating dose and repeated doses of CN-105 in healthy adult subjects. J Clin Pharmacol. 2017;57:770–776.
   PubMed Web of Science ®Google Scholar
• Evaluation of CN-105 in subject with acute supratentorial intracerebral hemorrhage (S-CATCH). 2018. Available from: https://clinicaltrials.gov/ct2/show/NCT03711903
   Google Scholar
• VanDusen KW, Eleswarpu S, Moretti EW, et al. MARBLE study investigators. The MARBLE study protocol: modulating apoe signaling to reduce brain inflammation, delirium, and postoperative cognitive dysfunction. J Alzheimers Dis. 2020;75(4):1319–1328.
   PubMed Web of Science ®Google Scholar
• Hankey GJ. Nerinetide before reperfusion in acute ischaemic stroke: déjà vu or new insights? Lancet. 2020;395:843–844.
   PubMed Web of Science ®Google Scholar